NDAORALCAPSULE
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LORABID (loracarbef) is an oral cephalosporin antibiotic approved in 1991 for bacterial infections. It is indicated for respiratory tract, urinary tract, and skin infections caused by susceptible organisms. The drug works by inhibiting bacterial cell wall synthesis through beta-lactam mechanism.
LOE Approaching
Product is in late-stage maturity with limited growth potential; commercial team likely focused on transition planning and line extensions rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LORABID offers limited career growth potential given its LOE-approaching lifecycle and minimal linked job count (0). Roles available tend to focus on defensive market management, pricing strategy, and regulatory maintenance rather than innovation or expansion.
Product ManagerField Sales Representative
Worked on LORABID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.